Skip to main content

THIS SITE IS INTENDED FOR US AUDIENCES.

Main navigation

  • Home
  • About Us
  • Products & Pipeline
  • News
  • Careers
  • Let's Connect

This form is intended for US audiences.

Reddy. Set. Let’s go!

 

By subscribing via email, you consent to receive periodic product updates and marketing communications. You may opt out at any time by clicking the ‘unsubscribe’ button provided in our emails. Further, you acknowledge that your subscription is subject to our Privacy Notice and Terms of Use.
 
Thank you for your interest. You can contact us directly at info@drreddysbiologics.com.

To report adverse events/side effects or product complaints,       
or to submit medical inquiries, contact the Medical Information Call Center:       
Hours of Operation: Monday–Friday 8 AM–8 PM EST       
Phone: 1-888-375-3784 (1-888-DRL-DRUG)       
Email: medinfo@drreddys.com

Reddy. Set. Let’s go!

Thank you for signing up to receive communications from Dr. Reddy’s.

For additional information, you can contact us directly at info@drreddysbiologics.com.

To report adverse events/side effects or product complaints,       
or to submit medical inquiries, contact the Medical Information Call Center:       
Hours of Operation: Monday–Friday 8 AM–8 PM EST       
Phone: 1-888-375-3784 (1-888-DRL-DRUG)       
Email: medinfo@drreddys.com

Thank You

For reaching out. A representative will contact you soon.

To report adverse events/side effects or product complaints,       
or to submit medical inquiries, contact the Medical Information Call Center:       
Hours of Operation: Monday–Friday 8 AM–8 PM EST       
Phone: 1-888-375-3784 (1-888-DRL-DRUG)       
Email: medinfo@drreddys.com

Body
Body

News

Body

May 21, 2024Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the US, Europe and UK Dr. Reddy’s gets exclusive commercialization rights in the United States (US) as well as semi-exclusive rights in Europe and United Kingdom (UK)View Article

Body

December 6, 2023Coya Therapeutics, Inc. and Dr. Reddy's Laboratories enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) Under the Agreement, Dr. Reddy's will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALSView Article

Body

January 20, 2023Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the US, Europe Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy's will now prepare to file in the United States, European Union and other regionsView Article

Footer

  • DR. REDDY'S GLOBAL
  • DR REDDY'S US
  • INVESTORS
  • CAREERS
  • PRIVACY
  • Terms of Use
  • COOKIE POLICY
  • Cookie Preferences
  • Linkedln

© 2024 Dr. Reddy's Laboratories, Inc. All rights reserved. RDYY-0624-655 June 2024

You are now leaving 
www.DrReddysBiologics.com